CA3075722A1 - Extended release formulations for intra-articular applications - Google Patents

Extended release formulations for intra-articular applications Download PDF

Info

Publication number
CA3075722A1
CA3075722A1 CA3075722A CA3075722A CA3075722A1 CA 3075722 A1 CA3075722 A1 CA 3075722A1 CA 3075722 A CA3075722 A CA 3075722A CA 3075722 A CA3075722 A CA 3075722A CA 3075722 A1 CA3075722 A1 CA 3075722A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
optionally
water
oxabicyclo
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3075722A
Other languages
English (en)
French (fr)
Inventor
Carlo Castagnoli
Andreas Fisch
Mathilde LORSCHEIDER
Manjali Laxman NEHARKAR
Bernd Ulrich Riebesehl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3075722A1 publication Critical patent/CA3075722A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3075722A 2017-11-10 2018-11-08 Extended release formulations for intra-articular applications Pending CA3075722A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762584589P 2017-11-10 2017-11-10
US62/584,589 2017-11-10
US201862743864P 2018-10-10 2018-10-10
US62/743,864 2018-10-10
PCT/IB2018/058788 WO2019092637A1 (en) 2017-11-10 2018-11-08 Extended release formulations for intra-articular applications

Publications (1)

Publication Number Publication Date
CA3075722A1 true CA3075722A1 (en) 2019-05-16

Family

ID=64402238

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3075722A Pending CA3075722A1 (en) 2017-11-10 2018-11-08 Extended release formulations for intra-articular applications

Country Status (23)

Country Link
US (1) US20210177824A1 (https=)
EP (1) EP3706710B1 (https=)
JP (1) JP7284750B2 (https=)
KR (1) KR20200087138A (https=)
CN (1) CN111278410A (https=)
AU (1) AU2018364685B2 (https=)
CA (1) CA3075722A1 (https=)
CL (1) CL2020001156A1 (https=)
DK (1) DK3706710T3 (https=)
ES (1) ES2981903T3 (https=)
FI (1) FI3706710T3 (https=)
HR (1) HRP20240808T1 (https=)
HU (1) HUE066971T2 (https=)
IL (2) IL305541A (https=)
LT (1) LT3706710T (https=)
MX (2) MX2020004477A (https=)
PL (1) PL3706710T3 (https=)
PT (1) PT3706710T (https=)
RS (1) RS65659B1 (https=)
SA (1) SA520411881B1 (https=)
SI (1) SI3706710T1 (https=)
TW (2) TWI813597B (https=)
WO (1) WO2019092637A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113015735B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物
US20230414601A1 (en) * 2020-11-30 2023-12-28 Lg Chem, Ltd. Injectable composition containing caspase inhibitor, and preparation method therefor
KR20240133027A (ko) 2023-02-28 2024-09-04 주식회사 포스테라헬스사이언스 올리고펩타이드를 포함하는 서방형 입자 및 이의 제조 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
DK3143026T3 (da) * 2014-05-13 2024-09-30 Novartis Ag Forbindelser og sammensætninger til induktion af chondrogenese

Also Published As

Publication number Publication date
PT3706710T (pt) 2024-06-27
TW201922245A (zh) 2019-06-16
PL3706710T3 (pl) 2024-08-05
JP7284750B2 (ja) 2023-05-31
HRP20240808T1 (hr) 2024-09-27
US20210177824A1 (en) 2021-06-17
IL274149B2 (en) 2024-02-01
AU2018364685B2 (en) 2021-05-20
IL305541A (en) 2023-10-01
RU2020115439A (ru) 2021-12-10
FI3706710T3 (fi) 2024-07-08
MX2020004477A (es) 2020-08-03
EP3706710A1 (en) 2020-09-16
EP3706710B1 (en) 2024-04-10
IL274149A (en) 2020-06-30
DK3706710T3 (da) 2024-07-08
LT3706710T (lt) 2024-07-10
TWI813597B (zh) 2023-09-01
AU2018364685A1 (en) 2020-03-26
TW202400164A (zh) 2024-01-01
IL274149B1 (en) 2023-10-01
CL2020001156A1 (es) 2020-10-30
SA520411881B1 (ar) 2024-01-04
HUE066971T2 (hu) 2024-09-28
RU2020115439A3 (https=) 2021-12-10
SI3706710T1 (sl) 2024-08-30
KR20200087138A (ko) 2020-07-20
WO2019092637A1 (en) 2019-05-16
CN111278410A (zh) 2020-06-12
MX2023007036A (es) 2023-06-28
RS65659B1 (sr) 2024-07-31
BR112020008806A2 (pt) 2020-10-20
ES2981903T3 (es) 2024-10-14
JP2021502337A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
ES2699692T3 (es) Sistema de depósito que comprende acetato de glatiramer
US20070077286A1 (en) Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle
US20150024031A1 (en) Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent
CN110709061B (zh) 抗沉淀的小分子药物制剂
AU2018364685B2 (en) Extended release formulations for intra-articular applications
US12186427B2 (en) Fulvestrant formulations and methods of their use
IL292079B2 (en) Aripiprazole prodrug compositions and uses thereof
CN113876724B (zh) 一种负载帕瑞昔布、白介素-4和牛血清白蛋白用于骨关节炎治疗的双层微球及其制备方法
CN118891032A (zh) 用于延长释放非诺贝特的微球
RU2786830C2 (ru) Препараты с пролонгированным высвобождением для внутрисуставного введения
HK40027680A (en) Extended release formulations for intra-articular applications
HK40027680B (en) Extended release formulations for intra-articular applications
JP6826167B2 (ja) アリピプラゾールプロドラッグ組成物
US11590077B2 (en) Fulvestrant formulations and methods of their use
BR112020008806B1 (pt) Composição farmacêutica adequada para injeção intra-articular, seu uso, e kit
CN117717524B (zh) 一种负载精氨酸的白蛋白基缓释微球及其制备方法与应用
CN116898824B (zh) 组胺h1受体拮抗剂缓释纳米粒及其制备方法、注射剂和应用
CA3082193C (en) Fulvestrant formulations and methods of their use
RU2800869C2 (ru) Составы фулвестранта и способы их применения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231010

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241102

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241102

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241102

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241107

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250630

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250630

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260105

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128